Zimmer loses hip lawsuit; Gynesonics gets a CPT code from AMA;

@FierceMedDev: OraSure gets FDA nod for emergency use of rapid Ebola test. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Intuitive awards grants to support training of its da Vinci robot using virtual reality. Article | Follow @VarunSaxena2

@EmilyWFierce: The FDA just approved the first 3-D printed drug. More from MedScape | Follow @EmilyWFierce

> Zimmer Biomet ($ZMH) was slapped with a $9.2 million verdict from a California jury for a man who had to replace a metal-on-metal Durom Cup. More

> The American Medical Association has given Gynesonics a CPT code for its transcervical uterine fibroid ablation device, which should help ease reimbursement processes. It's an alternative to surgery involving the highly controversial power morcellator. More

> The FDA has classified external upper esophageal sphincter (UES) compression devices as Class II. More

Biotech News

@FierceBiotech: ICYMI: Sorrento buys into biosimilars with a Chinese antibody deal. Story | Follow @FierceBiotech

@JohnCFierce: How to lose a billion dollars -- $AXON cap down to $1.28B, down about a billion from its IPO. | Follow @JohnCFierce

@DamianFierce: $SHPG first proposed a merger on July 10, meaning $BXLT lasted nine whole days before someone tried to buy it. | Follow @DamianFierce

> After years on the slide, things are looking up in biopharma R&D, report says. More

> Regeneron ups its research budget by 32% with eyes on new blockbusters. Story

> Shire goes public with a $30B bid to acquire Baxalta, expand rare-disease pipeline. Article

Pharma News

@FiercePharma: Sales of diabetes drugs in Japan are a key H2 performance gauge, Sanofi CEO says. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: Realizing that a proposed Shire deal with a pharma spinoff in the Chicago suburbs is exactly what this summer was missing. $SHPG $BXLT $ABBV | Follow @CarlyHFierce

> Lilly faces first trial over claims of Cymbalta withdrawal symptoms. Report

> Deal-minded Shire offers $30B for new spinoff Baxalta in public bid. News

Drug Delivery News

> Recommended chemotherapy administration method found underutilized. Report

> Emergent BioSolutions launches autoinjector to protect against chemical weapons attacks. Item

> NanoSmart's targeted cancer killer gains another orphan designation for Ewing's sarcoma. More

> Dauntless gets $12M in Series A to develop cancer med using intranasal platform. Story

> Northwestern bags $17.5M from NIH to develop implant for delivery of drugs that prevent HIV. Article

Pharma Manufacturing News

> GSK beefing up in U.S. drug and inhaler plant. Article

> FDA looks at Baxter Mexico plant for more saline supply. Report

> Wockhardt retrieves millions and millions of drugs in effort to win back FDA approval. Story

> FDA approves seizure drug made with 3-D technology. Item

> Generics maker Amneal revamping former J&J plant in Ireland. Article

Pharma Asia News

> Takeda submits post-marketing Actos study that shows no link to bladder cancer. News

> Merck eyes opportunity for omarigliptin filing with Japan's PMDA. Report

> Bayer sees Q2 bright spots in China pharma, but consumer health is more complicated. Story

> Sales of diabetes drugs in Japan are a key H2 performance gauge, Sanofi CEO says. More

> Amgen says Vectibix sales in Japan got Q2 boost on shipments to Takeda. Article

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.